Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bleximenib + Chemo in Pediatric/Young Adult Acute Leukemias
NCT05521087Phase 1Withdrawn
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2025
- Primary completion
- Sep 2026
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of bleximenib in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and acute leukemia of ambiguous lineage (ALAL), sponsored by Janssen Pharmaceutical. Primary endpoints: Number of Participants with Adverse Events and Number of Participants with Dose-Limiting Toxicity. Planned start Dec 2025; status: withdrawn.
02
Drugs
bleximenib
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)acute leukemia of ambiguous lineage (ALAL)
Beyond the preview
Go deeper on NCT05521087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05521087.